President, European Society for Translational Medicine (EUSTM),Vienna, Austria
ISSN: 2324-8769
Frequency: Quarterly
The Journal Molecular Medicine & Therapeutics (MMT) includes basic research aimed at understanding molecular mechanisms of disease, as well as translational research utilizing this information to develop new and improved molecular-targeted approaches for prevention, diagnosis, and therapy. The journal covers all aspects of molecular biology, pathophysiology and molecular therapeutics.
Molecular Medicine & Therapeutics is a subscription based Journal that provides a range of options to purchase our articles and also permits unlimited Internet Access to complete Journal content. It accepts research, review papers, online letters to the editors & brief comments on previously published articles or other relevant findings in SciTechnol. Articles submitted by authors are evaluated by a group of peer review experts in the field and ensures that the published articles are of high quality, reflect solid scholarship in their fields, and that the information they contain is accurate and reliable.
Performance of Commercial Interferon-γ Release Assays for Screening Latent Tuberculosis Infection: A Meta-Analysis
This meta-analysis was performed to systematically evaluate two interferon gamma release assays (IGRAs): ELISA and ELISPOT along with Tuberculin Skin Test (TST) in the detection of latent tuberculosis infection.
Parkinson’s Disease and Type-2 Diabetes: Methylglyoxal may be a Common Causal Agent; Carnosine could be Protective
The likelihood that the type-2 diabetes influences the incidence of Parkinson’s disease (PD), via increased generation of methylglyoxal (MG), is examined in the light of recent evidence. Animal experiments (mice and dogs) have shown that high glycemic index diets increase tissue MG levels, while low glycemic index diets in humans are associated with a decreased incidence of PD. Proteomic studies have revealed an increased activity of the carnosinase, CNDP2, in the substantia nigra of PD patients.
Genome-Scale Mapping of MicroRNA Signatures in Human Embryonic Stem Cell Neurogenesis
To date, lacking of a clinically-suitable source of engraftable human stem/progenitor cells with adequate neurogenic potential has been the major setback in developing effective cell-based therapies against a wide range of neurological disorders. Derivation of human embryonic stem cells (hESCs) provides a powerful tool to investigate the molecular controls in human embryonic neurogenesis as well as an unlimited source to generate the diversity of human neuronal cell types in the developing CNS for repair.
Novel Combinatorial Therapeutic Targeting of PAI-1(SERPINE1) Gene Expression in Alzheimer’s Disease
Accumulation of neurotoxic amyloid peptides (Aβ) in the brain, generated by β-site proteolytic processing of the amyloid precursor protein (APP), is the hallmark pathophysiologic feature of Alzheimer’s disease. The plasmin-activating cascade, in which urokinase (uPA) and tissue-type (tPA) plasminogen activators convert plasminogen to the broad-spectrum protease plasmin, appears to serve a protective, Aβ-clearing, role in the central nervous system.
